2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 09:12, 18 December 2023
, 18 December 2023→Bioavailability of NMN
| Line 92: | Line 92: | ||
NMN-HAP is a hydroxyapatite-based [[Nano‐Based Delivery Systems|nano-drug delivery system]] for nicotinamide mononucleotide that showed significantly enhancing NMN bioavailability and replenishing NAD+ levels in mice.{{pmid|37862582}} NMN-HAP is currently not available as supplement. | NMN-HAP is a hydroxyapatite-based [[Nano‐Based Delivery Systems|nano-drug delivery system]] for nicotinamide mononucleotide that showed significantly enhancing NMN bioavailability and replenishing NAD+ levels in mice.{{pmid|37862582}} NMN-HAP is currently not available as supplement. | ||
== | == Metabolism of NMN == | ||
=== Bioavailability === | |||
[[File:NMN NAD NAMN.png|thumb|Levels of NAD+ and NAMN in blood were increased by oral administration of 250mg NMN. NAD metabolome in blood was measured every 4 weeks. Three asterisks mean statistical significance: ''p''-value < 0.001.{{pmid|35479740}}]] | [[File:NMN NAD NAMN.png|thumb|Levels of NAD+ and NAMN in blood were increased by oral administration of 250mg NMN. NAD metabolome in blood was measured every 4 weeks. Three asterisks mean statistical significance: ''p''-value < 0.001.{{pmid|35479740}}]] | ||
[[Bioavailability]] is a crucial factor in the effectiveness of any dietary supplement, including Nicotinamide Mononucleotide (NMN). It refers to the proportion of a substance that enters the circulation when introduced into the body and is thus able to have an active effect. In the case of NMN, bioavailability determines how much of the compound reaches the bloodstream and subsequently contributes to NAD+ biosynthesis. | [[Bioavailability]] is a crucial factor in the effectiveness of any dietary supplement, including Nicotinamide Mononucleotide (NMN). It refers to the proportion of a substance that enters the circulation when introduced into the body and is thus able to have an active effect. In the case of NMN, bioavailability determines how much of the compound reaches the bloodstream and subsequently contributes to NAD+ biosynthesis. | ||
| Line 109: | Line 110: | ||
While various methods to enhance NMN’s bioavailability are being explored, conclusive evidence on the most effective form or administration method is still emerging. Current research is focused on understanding how different formulations affect NMN's absorption and utilization in the body. Future studies are expected to provide more insights and possibly lead to more effective NMN supplementation strategies. | While various methods to enhance NMN’s bioavailability are being explored, conclusive evidence on the most effective form or administration method is still emerging. Current research is focused on understanding how different formulations affect NMN's absorption and utilization in the body. Future studies are expected to provide more insights and possibly lead to more effective NMN supplementation strategies. | ||
=== Effect === | |||
* Taking 800 mg NMN per day increase blood cell NAD+ levels by ~43% in mild hypertension patients display significantly lower blood cell NAD+ levels.{{pmid|37718359}} | * Taking 800 mg NMN per day increase blood cell NAD+ levels by ~43% in mild hypertension patients display significantly lower blood cell NAD+ levels.{{pmid|37718359}} | ||
* Taking 300 mg NMN per day increase serum NAD+ levels by ~38%.{{pmid|35821806}} | * Taking 300 mg NMN per day increase serum NAD+ levels by ~38%.{{pmid|35821806}} | ||
* It is assumed that the NAD+ level increases continuously through the NMN intake until it reaches its maximum after 1-2 weeks.{{Citation needed}} | |||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
| Line 155: | Line 158: | ||
| | | | ||
|} | |} | ||
=== Clearance === | |||
It is currently assumed that NAD+ levels go back to baseline after 1-2 weeks of stopping NMN administration.{{Citation needed}} In clinical trials, the NAD+ levels were only measured 4 weeks after stopping administration | |||
== Controversy about NMN as Direct Precursor == | == Controversy about NMN as Direct Precursor == | ||